On Tuesday, shares in Dublin, Ireland headquartered Jazz Pharmaceuticals PLC recorded a trading volume of 494,354 shares. The stock ended at $103.88, rising 2.22% from the last trading session. The Company's shares have gained 0.76% in the last month. The stock is trading below its 50-day moving average by 9.39%. Furthermore, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 39.47.
On November 09th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $185 a share to $127 a share.
On November 28th, 2016, Jazz Pharmaceuticals announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness (ES) associated with narcolepsy. The Phase 3 narcolepsy study was a double-blind, placebo-controlled, multiple-center study evaluating the safety and efficacy of JZP-110 in the treatment of ES in adult patients with narcolepsy. The study enrolled 240 patients. Visit us today and access our complete research report on JAZZ at:
Hayward, California headquartered Anthera Pharmaceuticals Inc.'s stock finished yesterday's session 2.00% lower at $1.47 with a total trading volume of 319,626 shares. Shares of the Company, which focuses on the development and commercialization of medicines for patients with unmet medical needs, are trading below their 50-day moving average by 39.57%. The stock has an RSI of 28.90.
On December 06th, 2016, Anthera Pharma's Board of Directors announced that J. Craig Thompson has been promoted to CEO. The company stated that Paul Truex has stepped down from the CEO role and been appointed to the newly created role of Executive Chairman, where he will assume the responsibilities of the Chairman of the Board and continue to provide guidance to Anthera's senior executive team. The complimentary report on ANTH can be downloaded at:
At the closing bell on Tuesday, shares in Vancouver, Canada headquartered ProNAi Therapeutics Inc. rose 3.38%, ending the day at $1.53. The stock recorded a trading volume of 1.54 million shares, which was above its three months average volume of 593,000 shares. The Company's shares have advanced 7.75% in the last one month. The stock is trading 5.06% below its 50-day moving average. Moreover, shares of ProNAi Therapeutics, which develops and commercializes drugs based on its DNA interference (DNAi) technology platform for patients with cancer and hematological malignancies, have an RSI of 54.80.
On November 10th, 2016, ProNAi reported a net loss of $15.2 million for Q3 2016 compared to a net loss of $18.5 million for Q3 2015. At September 30th, 2016, ProNAi had $122.7 million in cash and cash equivalents compared to $150.2 million in cash and cash equivalents at December 31st, 2015. The company's Research and development expenses increased to $12.3 million for Q3 2016 from $8.3 million for Q3 2015. Register for free on Stock-Callers.com and access the latest research report on DNAI at:
Bannockburn, Illinois headquartered AveXis Inc.'s stock ended the day 1.40% higher at $54.19 with a total trading volume of 275,634 shares. The Company's shares have surged 53.04% over the previous three months and 204.44% on an YTD basis. The stock is trading 2.22% above its 50-day moving average and 41.58% above its 200-day moving average. Additionally, shares of AveXis, which engages in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 43.47.
On November 10th, 2016, AveXis posted Q3 2016 net loss of $21.1 million, or $0.87 per share, compared to a net loss of $9.9 million, or $1.32 per share, for Q3 2015. As of September 30th, 2016, AveXis had $263.6 million in cash and cash equivalents. The company's research and development expenses were $14.1 million for Q3 2016, compared to $6.3 million for Q3 2015.
On November 14th, 2016, research firm Stifel initiated a 'Hold' rating on the Company's stock, issuing a target price of $65 per share. Get free access to your research report on AVXS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA